These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22734188)

  • 1. [Troubling shortage of drugs].
    Kiefer B
    Rev Med Suisse; 2012 May; 8(342):1144. PubMed ID: 22734188
    [No Abstract]   [Full Text] [Related]  

  • 2. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
    Bender S; Flicker L; Rhodes R
    Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
    [No Abstract]   [Full Text] [Related]  

  • 3. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 4. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: business practices.
    Jones TM
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-54. PubMed ID: 19297719
    [No Abstract]   [Full Text] [Related]  

  • 6. Access to medication and drug company sales practices: setting priorities for critique and advocacy.
    Seiler N
    Am J Bioeth; 2003; 3(3):61. PubMed ID: 14594498
    [No Abstract]   [Full Text] [Related]  

  • 7. Introduction: Pharmaceutical firms and the right to health.
    de Campos TC; Pogge T
    J Law Med Ethics; 2012; 40(2):183-7. PubMed ID: 22789038
    [No Abstract]   [Full Text] [Related]  

  • 8. Global health challenges in the pharmaceutical world.
    Abraham J
    Health Econ Policy Law; 2009 Jan; 4(Pt 1):115-27. PubMed ID: 19099620
    [No Abstract]   [Full Text] [Related]  

  • 9. [Health care system: an ethical choice or a trade issue].
    Saegesser P
    Rev Med Suisse; 2012 Jun; 8(345):1299. PubMed ID: 22787734
    [No Abstract]   [Full Text] [Related]  

  • 10. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
    Meron D
    Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses.
    Mahinka SP; Sanzo KM
    Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000
    [No Abstract]   [Full Text] [Related]  

  • 12. Diversion controversy: hospital voices respond.
    Wilkinson R
    Hospitals; 1987 Apr; 61(8):118. PubMed ID: 3557388
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
    [No Abstract]   [Full Text] [Related]  

  • 14. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the pharmaceutical sector have a coresponsibility for the human right to health?
    Schroeder D
    Camb Q Healthc Ethics; 2011 Apr; 20(2):298-308. PubMed ID: 21435305
    [No Abstract]   [Full Text] [Related]  

  • 17. Human rights responsibilities of pharmaceutical companies in relation to access to medicines.
    Lee JY; Hunt P
    J Law Med Ethics; 2012; 40(2):220-33. PubMed ID: 22789042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why self-regulation does not work: resolving prescription corruption caused by excessive gift-giving by pharmaceutical manufacturers.
    Mehta RS
    Food Drug Law J; 2008; 63(4):799-821. PubMed ID: 19593922
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective.
    Ahmadiani S; Nikfar S
    Daru; 2016 May; 24(1):13. PubMed ID: 27141958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When names make claims: ethical issues in medical device marketing.
    Bramstedt KA
    Ethics Med; 2004; 20(2):47-57. PubMed ID: 15468483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.